<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02124941</url>
  </required_header>
  <id_info>
    <org_study_id>1311013082</org_study_id>
    <nct_id>NCT02124941</nct_id>
  </id_info>
  <brief_title>Glutamate-Glutamine Cycling (VCYC) During Cocaine Abstinence Using 13C-MRS</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <brief_summary>
    <textblock>
      Given prior evidence of reduced resting-state glucose uptake in prefrontal cortex (PFC) as
      measured by [18F]-FDG PET (Volkow 1992, 1993) and direct neurometabolic coupling of cortical
      glucose oxidation and glutamate transmission, we hypothesize that [13C]-MRS measures of VTCA
      and VCYC will be reduced in individuals abstinent from cocaine as compared to HCs. We will
      also explicitly explore potential relationships between VCYC and neurocognitive tests of PFC
      function and clinical outcomes (i.e., measures of relapse at 90-days outpatient follow-up).
      In addition to assessing resting-state glucose uptake in the PFC, we will explore whether
      open-label administration of either of three different pharmacological treatments (N-acetyl
      cysteine, riluzole, or pentoxifylline) increases VCYC, in cocaine users (CU) in comparison to
      their abstinence baseline.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>13C prefrontal cortex (PFC) glucose metabolism</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stop Signal Task (SST)</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>13C MRS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>13C MRS after 2 weeks of abstinence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>13C MRS after 4 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>13C MRS after 2 additional weeks of experimental medication (NAC, RIL, or PTX) or continued abstinence</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetyl cysteine</intervention_name>
    <arm_group_label>13C MRS after 4 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>riluzole</intervention_name>
    <arm_group_label>13C MRS after 4 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pentoxifylline</intervention_name>
    <arm_group_label>13C MRS after 4 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>13C MRS</intervention_name>
    <arm_group_label>13C MRS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Continued abstinence</intervention_name>
    <arm_group_label>13C MRS after 4 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 21-50 years

          2. Voluntary, written, informed consent

          3. Physically healthy

          4. DSM-IV criteria for Cocaine Abuse (305.60) or Cocaine Dependence (304.20)

          5. Documented evidence (by urine toxicology) of abstinence from cocaine (2 weeks for scan
             1 and 4 weeks for scan 2)

          6. For females, a negative serum or urine pregnancy (β-HCG) test.

        Exclusion Criteria:

          1. A history of other substance dependence (e.g., alcohol, opiates, sedative hypnotics),
             except for nicotine

          2. A primary DSM-IV Axis I major psychiatric disorder (e.g., schizophrenia, bipolar
             disorder, major depression, etc.) as determined by the Structured Clinical Interview
             for DSM-IV (SCID)

          3. A history of significant medical (e.g., cardiovascular, diabetic/metabolic) or
             neurological (e.g., cerebrovascular, seizure, traumatic brain injury) illness

          4. Current use of psychotropic and/or potentially psychoactive prescription medications

          5. Medical contraindications to participation in a magnetic resonance imaging procedure
             (e.g., ferromagnetic implants/foreign bodies, claustrophobia, cardiac pacemaker,
             prosthetic valve, otologic implant, etc.)

          6. For females, physical or laboratory (β-HCG) evidence of pregnancy

          7. For subjects interested in pharmacotherapy component, history of allergies to NAC,
             RIL, or PTX and current elevation on liver function tests above twice the normal
             limit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Malison, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Costeines, MSW</last_name>
    <phone>203-520-6398</phone>
    <email>jessica.costeines@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Connecticut Mental Health Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Robert Malison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2014</study_first_submitted>
  <study_first_submitted_qc>April 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2014</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentoxifylline</mesh_term>
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
    <mesh_term>Riluzole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

